格列齐特、甲钴胺及其联合用药对糖尿病大鼠周围神经形态学改变及神经生长因子含量的影响

Effect of methylcobalamin,gliclazide and combined application of both on sciatic nerve morphology and nerve growth factor contents in streptozotocin-induced diabetic rats

目的观察格列齐特、甲钴胺及其联合用药对糖尿病大鼠周围神经形态学改变及神经生长因子含量的影响。方法采用链脲佐菌素致糖尿病大鼠模型,以组织学方法观察药物对糖尿病大鼠坐骨神经形态学改变的影响;以酶联免疫方法测定血清中神经生长因子含量;以免疫组织化学法观察坐骨神经组织内神经生长因子的含量变化。结果格列齐特、甲钴胺及其联合用药对糖尿病大鼠坐骨神经形态学改变有保护作用;对血清神经生长因子含量减少有提高作用;对坐骨神经组织中神经生长因子的含量虽无明显影响,但对坐骨神经轴突内神经生长因子的减少有提高作用。格列齐特与甲钴胺联合应用对以上指标的改善均未发现有明显性提高。结论格列齐特、甲钴胺及其联合用药对糖尿病大鼠周围神经病变具有保护作用;与单独用药相比,格列齐特与甲钴胺联合应用未见有明显性疗效增强作用。

Aim To investigate the curative effect and the mechanism of methylcobalamin,gliclazide and combined application of both on diabetic peripheral neuropathy （DPN） in streptozotocin-induced diabetic （STZ-D） rats. Methods STZ-D rats were administered with drugs orally for 8 weeks after streptozotocin treatment. Morphologies of sciatic nerve were observed with histological method. Nerve growth factor （NGF） contents in plasma or in sciatic nerve tissues were determined by ELISA kit or immunohistochemistry. Resuits Morphological degeneration in sciatic nerve, decrease of NGF concertration in plasma, as well as in nerve axis cylinder, in diabetic rats was all ameliorated by methylcobalamin and/or gliclazide. However, no significant differences in morphology and NGF contents were found between single drug treated groups and combined application group. Conclusions The observations suggest that methylcobalamin, gliclazide and combined application are effective in treating DPN in STZ-D rats. No significantly enhanced effect is found in combined application group as compared with methylcobalamin or gliclazide group.